Smith & Nephew (LON:SN) Downgraded by Royal Bank Of Canada to “Sector perform”

Royal Bank Of Canada downgraded shares of Smith & Nephew (LON:SN) to a sector perform rating in a research report released on Wednesday morning, Marketbeat reports. The firm currently has GBX 1,350 price objective on the stock, down from their previous price objective of GBX 1,700.

Several other equities analysts have also recently issued reports on SN. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th. Citigroup raised their target price on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Panmure Gordon reaffirmed a “hold” rating and issued a GBX 1,200 price target on shares of Smith & Nephew in a report on Tuesday, December 9th. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of GBX 1,381.33.

Smith & Nephew Stock Up 0.0%

LON:SN opened at GBX 1,206 on Wednesday. The company has a current ratio of 2.51, a quick ratio of 0.84 and a debt-to-equity ratio of 70.22. The business’s 50-day moving average price is GBX 1,295.98 and its 200-day moving average price is GBX 1,259.51. The firm has a market capitalization of £13.22 billion, a price-to-earnings ratio of 43.42, a P/E/G ratio of 0.46 and a beta of 0.62.

Insider Activity

In related news, insider Deepak Nath sold 1,240 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total value of £15,586.80. 0.19% of the stock is owned by corporate insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.